Targeting Bmi1 For The Treatment Of Endometrial Cancer

Objective: Advanced or recurrent endometrial cancer carries a dismal prognosis with a high rate of chemoresistance. Strategies to improve response rates are greatly needed. BMI1, a member of the polycomb repressor complex-1, regulates chromatin structure and is indispensable for self-renewal of both normal and cancer stem cells. BMI1 is upregulated in many malignancies including endometrial cancer. Targeting BMI1 inhibits cell viability and leads to caspase-dependent apoptosis in endometrial cancer cell lines. Here we examine BMI1 levels in patient tissue samples and demonstrate in vivo efficacy of anti-BMI1 therapy.